Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0027 Transporter Info
Gene Name SLC22A12
Transporter Name Urate anion exchanger 1
Gene ID
116085
UniProt ID
Q96S37
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Losartan

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Losartan inhibits the transportation of Uric acid by SLC22A12 (Ki = 0.0077 microM) [1]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Oocytes-URAT1

  DT Modulation 2

 Losartan inhibits the transportation of Uric acid by SLC22A12 (IC50 = 570.5 microM) [3]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-URAT1

  Benzbromarone

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzbromarone inhibits the transportation of Uric acid by SLC22A12 (IC50 = 0.13 microM) [3]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-URAT1

  DT Modulation 2

 Benzbromarone inhibits the transportation of Uric acid by SLC22A12 [2]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-URAT1

  Lesinurad

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lesinurad modulates the activity of SLC22A12 [4]

  DT Modulation 2

 Lesinurad inhibits the activity of SLC22A12 [5]

  Telmisartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Telmisartan inhibits the transportation of Uric acid by SLC22A12 (Ki = 0.0182 microM) [1]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Oocytes-URAT1

  Probenecid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Probenecid inhibits the transportation of Uric acid by SLC22A12 (IC50 = 50 microM) [2]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-URAT1

  Sulfinpyrazone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sulfinpyrazone inhibits the transportation of Uric acid by SLC22A12 (IC50 = 100 microM) [2]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-URAT1

  Fenofibric acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fenofibric acid inhibits the transportation of Uric acid by SLC22A12 (IC50 = 35.68 microM) [3]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-URAT1

  Pyrazinamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pyrazinamide affects the activity of SLC22A12 [7]

  Irbesartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Irbesartan inhibits the activity of SLC22A12 [8]

Drug in Phase 3 Trial

  Pratosartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pratosartan inhibits the transportation of Uric acid by SLC22A12 (Ki = 0.0067 microM) [1]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Oocytes-URAT1

Drug in Phase 1 Trial

  Sodium arsenite

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sodium arsenite increases the expression of SLC22A12 [9]

Investigative Drug

  Morin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Morin inhibits the transportation of Uric acid by SLC22A12 (IC50 = 2 microM) [2]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-URAT1

  DT Modulation 2

 Morin inhibits the transportation of Uric acid by SLC22A12 (Ki = 5.74 microM) [2]

Affected Drug/Substrate

 Uric acid Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-URAT1

  Uric acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Uric acid inhibits the transportation of Oxypurinol by SLC22A12 (IC50 = 170 microM) [6]

Affected Drug/Substrate

 Oxypurinol Modulation Type Inhibition

Cell System

 Oocytes-URAT1
References
1 Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007 Jan;320(1):211-7.
2 Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells. Drug Metab Dispos. 2007 Jun;35(6):981-6.
3 Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med. 2010;49(2):89-94.
4 Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
5 Lesinurad: A Review in Hyperuricaemia of Gout. Drugs Aging. 2017 May;34(5):401-410.
6 Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos. 2005 Dec;33(12):1791-5.
7 Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol. 2004 Jan;15(1):164-73.
8 Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters. J Pharmacol Sci. 2010;114(1):115-8.
9 Cellular and Molecular Effects of Prolonged Low-Level Sodium Arsenite Exposure on Human Hepatic HepaRG Cells. Toxicol Sci. 2018 Apr 1;162(2):676-687.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.